AcouSort (ACOU) investor relations material

Executive summary

• Net sales increased to SEK 2,147 thousand in Q1 2026 from SEK 1,595 thousand year-over-year, with a reduced loss before tax of SEK -2,369 thousand compared to SEK -4,022 thousand.

• Significant events included a new feasibility project with a major international manufacturer and an amended license agreement with Werfen, resulting in a USD 1.3 million royalty prepayment.

• Strategic focus remains on expanding OEM partnerships and strengthening positions in diagnostics, cell therapy, and lab automation.

Financial highlights

• Group net sales for Q1 2026 were SEK 2,147 thousand, up from SEK 1,595 thousand year-over-year.

• Result before tax improved to SEK -2,369 thousand from SEK -4,022 thousand year-over-year.

• Cash and cash equivalents at quarter-end were SEK 14,572 thousand, up from SEK 3,448 thousand year-over-year.

• Equity ratio increased to 52% from 41% year-over-year.

• Royalty income for the quarter was SEK 1,431 thousand, with a significant prepayment from Werfen.

Outlook and guidance

• Fully funded into 2027 due to Werfen royalty prepayment and current cash position.

• Continued focus on developing partnerships and expanding presence in diagnostics, cell therapy, and lab automation.

• Plans to attend key industry conferences and pursue new OEM projects throughout 2026.